JPWO2022047583A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022047583A5
JPWO2022047583A5 JP2023537445A JP2023537445A JPWO2022047583A5 JP WO2022047583 A5 JPWO2022047583 A5 JP WO2022047583A5 JP 2023537445 A JP2023537445 A JP 2023537445A JP 2023537445 A JP2023537445 A JP 2023537445A JP WO2022047583 A5 JPWO2022047583 A5 JP WO2022047583A5
Authority
JP
Japan
Prior art keywords
group
alkyl
compound
acyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539390A5 (https=
JP2023539390A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051214 external-priority patent/WO2022047583A1/en
Publication of JP2023539390A publication Critical patent/JP2023539390A/ja
Publication of JPWO2022047583A5 publication Critical patent/JPWO2022047583A5/ja
Publication of JP2023539390A5 publication Critical patent/JP2023539390A5/ja
Pending legal-status Critical Current

Links

JP2023537445A 2020-09-02 2021-09-02 ニトロ化サイロシビン誘導体ならびに5-ht2a受容体を調節するためおよび精神障害を処置するためのその使用 Pending JP2023539390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073534P 2020-09-02 2020-09-02
US63/073,534 2020-09-02
PCT/CA2021/051214 WO2022047583A1 (en) 2020-09-02 2021-09-02 Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder

Publications (3)

Publication Number Publication Date
JP2023539390A JP2023539390A (ja) 2023-09-13
JPWO2022047583A5 true JPWO2022047583A5 (https=) 2024-09-04
JP2023539390A5 JP2023539390A5 (https=) 2024-09-04

Family

ID=80492288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537445A Pending JP2023539390A (ja) 2020-09-02 2021-09-02 ニトロ化サイロシビン誘導体ならびに5-ht2a受容体を調節するためおよび精神障害を処置するためのその使用

Country Status (10)

Country Link
US (1) US20230040398A1 (https=)
EP (1) EP4208446A4 (https=)
JP (1) JP2023539390A (https=)
KR (1) KR20230061473A (https=)
CN (1) CN116782896A (https=)
AU (1) AU2021336667A1 (https=)
CA (1) CA3191095A1 (https=)
IL (1) IL301028A (https=)
MX (1) MX2023002619A (https=)
WO (1) WO2022047583A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
EP4291549A4 (en) 2021-02-12 2025-01-22 Enveric Biosciences Canada Inc. MULTISUBSTITUENT PSILOCYLYBINDER DERIVATIVES AND METHODS OF USE
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
KR20250097973A (ko) * 2022-11-18 2025-06-30 인베릭 바이오사이언시스 캐나다 인크. 치환된 n-프로필아민 융합 헤테로사이클릭 메스칼린 유도체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083918A1 (en) * 1998-06-08 2001-03-21 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
KR20030046395A (ko) * 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 인돌 유도체를 사용하여 안압을 감소시키는 방법
DE60222396T2 (de) * 2001-03-29 2008-05-15 Eli Lilly And Co., Indianapolis N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
EP1747779A1 (en) * 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
CN103601662B (zh) * 2013-11-21 2016-04-06 深圳市药品检验所 一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用
WO2015140799A1 (en) * 2014-03-18 2015-09-24 Carmel-Haifa University Economic Corp. Ltd Methods for improving cognitive function via modulation of quinone reductase 2
EP3532492A4 (en) * 2016-10-26 2020-10-14 University of Florida Research Foundation, Incorporated HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYZERS
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US10640508B2 (en) * 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers

Similar Documents

Publication Publication Date Title
JP6905609B2 (ja) 癌の処置のためのウリジンのジオキソラン類似体
EP2816053B1 (en) Base-protected oligonucleotide
EA004771B1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
JP2024019735A5 (https=)
CN108350016B (zh) 抗病毒四氢呋喃衍生物
JPH01301691A (ja) 新規ヌクレオチド誘導体
JP2021517126A5 (https=)
EP0357571A2 (en) Pyrimidine nucleosides
JPS6254118B2 (https=)
WO2005014525A2 (en) Bi-aryl compound having immunosuppressive activity
JPWO2022256842A5 (https=)
GB1601020A (en) 2'-deoxy-5 (2-halogenovinyl)-uridines
PT1689726E (pt) Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores
JP2023002701A5 (https=)
JPWO2022047583A5 (https=)
JPWO2022036297A5 (https=)
JPWO2021195533A5 (https=)
Ali et al. Methods for the synthesis of α-heterocyclic/heteroaryl-α-aminophosphonic acids and their esters.
JPWO2021030555A5 (https=)
JPH05509307A (ja) プリンの抗ウイルス性ホスホノ―アルケン誘導体
JPWO2021219070A5 (https=)
US20230157996A1 (en) Small-molecule inhibitor targeting eb virus nuclear antigen protein, preparation method and use thereof
US12473305B2 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
JP2007538042A5 (https=)
JPWO2022047579A5 (https=)